Covid 19 Research using Clinical Trials (Home Page)
Report for D009190: Myelodysplastic Syndromes NIH
(Synonyms: Myelody, Myelodys, Myelodysp, Myelodyspl, Myelodyspla, Myelodysplasti, Myelodysplastic, Myelodysplastic S, Myelodysplastic Sy, Myelodysplastic Syn, Myelodysplastic Syndr, Myelodysplastic Syndrom, Myelodysplastic Syndrome, Myelodysplastic Syndromes)
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (2)
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug127 | Azacitidine Wiki | 1.00 |
| drug34 | ALX148 Wiki | 1.00 |
Correlated MeSH Terms (2)
| Name (Synonyms) | Correlation | |
|---|---|---|
| D011289 | Preleukemia NIH | 1.00 |
| D013577 | Syndrome NIH | 0.13 |
Correlated HPO Terms (0)
| Name (Synonyms) | Correlation |
|---|
There is one clinical trial.
Clinical Trials
1 A Phase 1/2 Study of ALX148 in Combination With Azacitidine in Patients With Higher Risk Myelodysplastic Syndrome (MDS)
This Phase 1/2 clinical study will evaluate ALX148 in combination with azacitidine for the treatment of patients with higher risk myelodysplastic syndrome (MDS).
NCT04417517 Higher Risk Myelodysplastic Syndromes Drug: ALX148 Drug: Azacitidine MeSH:Preleukemia Myelodysplastic Syndromes Syndrome
HPO:Myelodysplasia
Primary Outcomes
Description: Number of participants with a DLT
Measure: Phase 1: Dose Limiting Toxicities (DLT) Time: Up to 28 days
Description: Number of participants achieving a response per International Working Group (IWG) criteria
Measure: Phase 2: Objective response rate (ORR) Time: Approximately 6 months
HPO Nodes
HP:0002863: Myelodysplasia
Genes 94
FANCM GINS1 TERC FANCG FANCG SF3B1 ELANE SRP54 FANCI TET2 HAX1 TET2 GATA2 LIG4 RPS14 BRIP1 BUB3 GFI1B TCIRG1 CALR ATRX RFWD3 FANCF DNAJC21 TRIP13 XRCC2 PIGA FANCC BRAF MAD2L2 DDX41 RECQL4 FANCB BUB1B TERT BUB1 SH2B3 RUNX1 PALB2 BRCA2 MYSM1 NAGS NBEAL2 ERCC4 ASXL1 SBDS UBE2T EFL1 TP53 JAK2 RAD51C RPS14 CEP57 JAK2 SBDS SMARCD2 FANCE TET2 TINF2 RAF1 JAK2 KIT SRP54 SRP54 BRCA1 PTPN11 RAD51 SF3B1 MPL RFWD3 TET2 SAMD9 SLX4 ASXL1 TET2 DKC1 TET2 DNAJC21 TET2 FANCL RPS19 GATA2 FANCA GFI1 SRSF2 MPL MPL GATA2 HSPA9 THPO ATRX FANCD2 ERBB3 SRP72 Protein Mutations 22
C282Y C283Y D835Y H63D I332E R132C R132G R132H R132L R132S R132V R140L R140Q R140W R172G R172K R172M R172S R172W S1612C S239D T315I SNP 0
Primary Outcomes
Description: Number of participants with a DLT
Measure: Phase 1: Dose Limiting Toxicities (DLT) Time: Up to 28 daysDescription: Number of participants achieving a response per International Working Group (IWG) criteria
Measure: Phase 2: Objective response rate (ORR) Time: Approximately 6 months